Skip To Main Content

Transplantační medicína

Nejnovější trendy

Prozkoumejte nejčtenější články a videa na Campus Sanofi

Seřadit

A phase III randomized trial evaluating alirocumab 300 mg every 4 weeks as monotherapy or add-on to statin: ODYSSEY CHOICE I

Roth Eli M et al. Atherosclerosis vol. 254 (2016): 254-262

A phase III randomized trial evaluating alirocumab 300 mg every 4 weeks as monotherapy or add-on to statin: ODYSSEY CHOICE I

Roth Eli M et al. Atherosclerosis vol. 254 (2016): 254-262

A phase III randomized trial evaluating alirocumab 300 mg every 4 weeks as monotherapy or add-on to statin: ODYSSEY CHOICE I

Roth Eli M et al. Atherosclerosis vol. 254 (2016): 254-262

A phase III randomized trial evaluating alirocumab 300 mg every 4 weeks as monotherapy or add-on to statin: ODYSSEY CHOICE I

Roth Eli M et al. Atherosclerosis vol. 254 (2016): 254-262

One minute to ignite new thinking in COPD

Understanding type 2 inflammation* may help shed light on why some patients continue to exacerbate. Watch this video to learn how.1

The Impact of Exacerbations in COPD

Role of type 2 Inflammation

Quality of life and symptom measurement in COPD Patients

Videotallenne: Beyfortus® -valmisteen oikea ja turvallinen käyttö

국소 진행성 위암 환자에서 근치적 복강경 수술 후 지연된 보조화학요법이 장기 예후에 미치는 영향

Impact of chemotherapy delay on long-term prognosis of laparoscopic radical surgery for locally advanced gastric cancer: a pooled analysis of four randomized controlled trials
Zhong Q, et al. Gastric Cancer. 2024 Sep;27(5):1100-1113.

Toujeo - Rozpoczynanie i zamiana z innej insuliny

¡Vacúnate y vacuna a tus pacientes lo antes posible!

¡La INFLUENZA es mucho más que un resfriado común!
Conoce más sobre la INFLUENZA y sus complicaciones, así como de la importancia de la vacunación con la vacuna tetravalente en su presentación vial multidosis